RedHill Biopharma (RDHL) Debt to Equity (2020 - 2022)

RedHill Biopharma (RDHL) has 3 years of Debt to Equity data on file, last reported at -$2.38 in Q4 2022.

• Debt to Equity for Q4 2022 came in at -$2.38, down 112.63% year-over-year; the trailing twelve-month figure through Dec 2022 was -$2.38 (down 112.63% YoY), and the FY2022 annual result was -$2.38, down 112.63% from the prior year.
• Debt to Equity slipped to -$2.38 in Q4 2022 per RDHL's latest filing, from $18.84 in the prior quarter.
• Over five years, Debt to Equity peaked at $18.84 in Q4 2021 and troughed at -$2.38 in Q4 2022.
• A 3-year average of $9.4 and a median of $11.74 in 2020 frame the typical range for Debt to Equity.
• The sharpest annual moves came in 2021 and 2022: Debt to Equity soared 60.5% in 2021, then plunged 112.63% in 2022.
• A 3-year view of Debt to Equity shows it stood at $11.74 in 2020, then jumped by 60.5% to $18.84 in 2021, then sank by 112.63% to -$2.38 in 2022.
• Business Quant data shows RDHL's Debt to Equity at -$2.38 in Q4 2022, $18.84 in Q4 2021, and $11.74 in Q4 2020.